Cedars-Sinai Medical Center

Prometheus Biosciences, Inc.

Qu Biologics Inc.

Dermot McGovern

Stephan R Targan

Dalin Li

Jerome I Rotter

Janine Bilsborough

Harold David Gunn

Kent D Taylor

Marla C Dubinsky

David W Mullins

Laurens Kruidenier

Mahyar Sabripour

Xiuqing Guo

Mark Bazett

Shirin Kalyan

Momir Bosiljcic

Philip Fleshner

Monan Angela Zhang

Talin Haritunians

Marcel Thalen

Boyko Traychev Kabakchiev

Ho Pan Sham

Rebecca Gonsky

Richard L Deem

The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

Kit comprising contiguous nucleobases, including position 76, of RS5745994

The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.

Therapeutically triggering an innate immune response in a target tissue

Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.

Methods of diagnosing inflammatory bowel disease through RNASET2

Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)

Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease

The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.

Methods of predicting the need for surgery in crohn's disease

Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.

Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy

Growing community of inventors

Los Angeles, CA, United States of America

Dermot McGovern